PIM
VRTX icon

Provident Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Provident Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.9M Sell
147,620
-1,638
-1% -$764K 6.55% 2
2025
Q4 		$67.7M Sell
149,258
-4,148
-3% -$1.79M 6.16% 4
2025
Q3 		$60.1M Sell
153,406
-5,301
-3% -$2.22M 5.3% 4
2025
Q2 		$70.7M Buy
158,707
+2,382
+2% +$1.1M 6.04% 4
2025
Q1 		$75.8M Buy
156,325
+1,259
+0.8% +$587K 7.14% 2
2024
Q4 		$62.4M Sell
155,066
-439
-0.3% -$203K 5.96% 7
2024
Q3 		$72.3M Sell
155,505
-4,357
-3% -$2.09M 6.45% 3
2024
Q2 		$74.9M Sell
159,862
-263
-0.2% -$114K 6.82% 3
2024
Q1 		$66.9M Sell
160,125
-194
-0.1% -$82K 5.9% 5
2023
Q4 		$65.2M Sell
160,319
-850
-0.5% -$314K 6.16% 4
2023
Q3 		$56M Sell
161,169
-1,060
-0.7% -$371K 6.18% 5
2023
Q2 		$57.1M Sell
162,229
-815
-0.5% -$275K 6.04% 4
2023
Q1 		$51.4M Buy
163,044
+2,317
+1% +$695K 5.57% 5
2022
Q4 		$46.4M Sell
160,727
-1,300
-0.8% -$396K 5.5% 5
2022
Q3 		$46.9M Sell
162,027
-7,328
-4% -$2.11M 6.01% 3
2022
Q2 		$47.7M Sell
169,355
-17,959
-10% -$4.81M 5.62% 4
2022
Q1 		$48.9M Buy
187,314
+2,135
+1% +$507K 4.68% 9
2021
Q4 		$40.7M Buy
185,179
+1,813
+1% +$353K 3.67% 16
2021
Q3 		$33.3M Buy
183,366
+6,531
+4% +$1.28M 3.18% 20
2021
Q2 		$35.7M Buy
+176,835
New +$37M 3.44% 19

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Provident Investment Management's VRTX Position: Q1 2026 in Review

Provident Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q1 2026, selling an estimated $764K and leaving 147,620 shares worth $65.9M. The position accounts for 6.55% of the portfolio, ranked #2.

Provident Investment Management first reported a position in VRTX in Q2 2021 and has held it in 20 quarters since. The position peaked at $75.8M in Q1 2025. 1,689 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Provident Investment Management held 147,620 shares of Vertex Pharmaceuticals worth $65.9M as of Q1 2026.
  • Provident Investment Management sold 1,638 Vertex Pharmaceuticals shares in Q1 2026, an estimated $764K.
  • Vertex Pharmaceuticals made up 6.55% of Provident Investment Management's portfolio in Q1 2026, its #2 holding.
  • Provident Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Provident Investment Management's Vertex Pharmaceuticals position peaked at $75.8M in Q1 2025.
  • 1,689 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Provident Investment Management's 13F filing for Q1 2026, filed 13 May 2026.